Ziprasidone for Agitation or Psychosis in Dementia: Four Cases

Cole, Steven P.; Saleem, Rehan; Shea, William P.; Sedler, Mark J.; Sablosky, Marilyn; Jyringi, Darlene; Smith, Angela

doi:10.2190/namg-xxgg-wdvy-gx04

“…Aside from antipsychotic effects on hallucinations and delusions, 252 other ziprasidone benefits include effects on agitated behavior, [253][254][255][256] anxiety, 257 depression, 250,251,258,259 sleep, 260 and cognition. 251,261 Although results from controlled studies in dementia are lacking, in three frail elderly patients with dementia, ziprasidone was effective in improving psychosis, agitation, depression, and cognition in each case.…”

Section: Modafinilmentioning

confidence: 99%

Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications

Lauterbach

¹

,

Shillcutt²,

Victoroff³

et al. 2010

JNP

View full text Add to dashboard Cite

In Part I of this report, the authors reviewed preclinical and clinical evidence of neuroprotection by psychotropics and proposed criteria to predict translational neuroprotection. Here, the authors review a broad array of neuroprotective mechanisms and, based on evidence reviewed in Part I, consider agents with pharmacodynamic mechanisms of action that may be associated with neuroprotection. The neuroprotective potential of the pharmacodynamic mechanisms discussed here are held in common with drugs that evidenced neuroprotective potential in Part I. The agents examined here have symptomatic utility in neurodegenerative disease neuropsychiatric disorders and combine the most promising pharmacodynamic mechanisms yet have received insufficient research to date. Modafinil, duloxetine, ziprasidone, s-zopiclone, and ramelteon are evaluated in terms of their putative neuropsychiatric symptomatic and heuristic neuroprotective disease-modifying potentials. The authors review these agents in terms of their potential for clinical neuroprotection and suggest a criterion-based research agenda for future studies of their neuroprotective potential. Further research is needed with regard to the 10 translational neuroprotective candidate criteria, neuroprotective clinical trials, the correlation of psychotropic pharmacodynamic mechanisms with neuroprotective actions, and the translational predictive utility of the proposed candidate criteria.

show abstract

“…Aside from antipsychotic effects on hallucinations and delusions, 252 other ziprasidone benefits include effects on agitated behavior, [253][254][255][256] anxiety, 257 depression, 250,251,258,259 sleep, 260 and cognition. 251,261 Although results from controlled studies in dementia are lacking, in three frail elderly patients with dementia, ziprasidone was effective in improving psychosis, agitation, depression, and cognition in each case.…”

Section: Methodsmentioning

confidence: 99%

Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications

Lauterbach¹,

Shillcutt²,

Victoroff³

et al. 2010

Journal of Neuropsychiatry

View full text Add to dashboard Cite

In Part I of this report, the authors reviewed preclinical and clinical evidence of neuroprotection by psychotropics and proposed criteria to predict translational neuroprotection. Here, the authors review a broad array of neuroprotective mechanisms and, based on evidence reviewed in Part I, consider agents with pharmacodynamic mechanisms of action that may be associated with neuroprotection. The neuroprotective potential of the pharmacodynamic mechanisms discussed here are held in common with drugs that evidenced neuroprotective potential in Part I. The agents examined here have symptomatic utility in neurodegenerative disease neuropsychiatric disorders and combine the most promising pharmacodynamic mechanisms yet have received insufficient research to date. Modafinil, duloxetine, ziprasidone, s-zopiclone, and ramelteon are evaluated in terms of their putative neuropsychiatric symptomatic and heuristic neuroprotective disease-modifying potentials. The authors review these agents in terms of their potential for clinical neuroprotection and suggest a criterion-based research agenda for future studies of their neuroprotective potential. Further research is needed with regard to the 10 translational neuroprotective candidate criteria, neuroprotective clinical trials, the correlation of psychotropic pharmacodynamic mechanisms with neuroprotective actions, and the translational predictive utility of the proposed candidate criteria.

show abstract

“…Case reports have found benefit with oral and injectable forms. 12 Antidepressants. In the CitAD study, which was a placebo-controlled randomized trial,…”

Section: Pharmacologic Treatmentsmentioning

confidence: 99%

Threatening to burn the house down

Malhi¹,

Kiani²

2021

CP

0

View full text Add to dashboard Cite

show abstract

Ziprasidone for Agitation or Psychosis in Dementia: Four Cases

Abstract: These case reports suggest that oral ziprasidone may be an effective and safe medication for the treatment of agitation or psychosis in patients with dementia.

Cited by 14 publications

References 17 publications

Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications

Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications

Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications

Threatening to burn the house down

Contact Info

Product

Resources

About